66th ASH Annual Meeting: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis

Symposia: Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies Oral and Poster Abstracts
Oral

Research, Bleeding and Clotting, Autoimmune disorders, MDS, Anticoagulant Drugs, Adult, Epidemiology, Clinical Practice (Health Services and Quality), Autoimmune hemolytic anemia, Elderly, Translational Research, Clinical Research, Health outcomes research, Health disparities research, Thromboembolism, Chronic Myeloid Malignancies, Pediatric, Diseases, Real-world evidence, Treatment Considerations, Thrombotic disorders, Registries, Non-Biological therapies, Adverse Events, Young adult , Myeloid Malignancies, Survivorship, Study Population, Human, Maternal Health

Room 6CF (San Diego Convention Center)

Moderators:

Ghadeer Dawwas, PhD, MSc, MBA, BPharm, and Anna L. Parks, MD, University of Utah

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

697

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

François Laliberté, MA¹^*, Behnood Bikdeli, MD, MS²^*, Veronica Ashton, MPH^3,4^*, Guillaume Germain, MSc⁵^*, Julien Boudreau, MA¹^*, Manasvi Sundar⁶^*, Sean D MacKnight, MScPH¹^*, Brahim Bookhart, MPH, MBA⁴^*, Dereck Wentworth, PharmD⁴^*, Shawn Murphy, MD⁷^* and Gregory Piazza, MD, MS²^*

¹Groupe d'analyse, Ltée, Montreal, QC, Canada
²Brigham and Women’s Hospital, Boston, MA
³Johnson & Johnson Innovative Medicine, Titusville, NJ
⁴Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, NJ
⁵Groupe d'analyse, Ltée, Montréal, QC, Canada
⁶Analysis Group, Inc., Los Angeles, CA
⁷Mass General Brigham, Research Information Science & Computing, Somerville, MA

4:45 PM

698

Late Venous Thromboembolic Events in Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study

Rohith Jesudas, MBBS¹, Lei Wang²^*, Yan Chen³^*, Sedigheh Mirzaei⁴^*, Siddhant Taneja⁵^*, Kirsten K Ness, PT, PhD⁶^*, Matthew J. Ehrhardt, MD⁷, Stephanie B Dixon, MD, MPH⁵, Bonnie Ky, MD⁸^*, Melissa M. Hudson, MD⁹, Clifford M. Takemoto, MD¹⁰, Daniel M. Green, MD¹¹ and Daniel A. Mulrooney, MD, MS¹²

¹St Judes Children's Research Hospital, Memphis, TN
²Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN
³St. Jude Children's Research Hospital, Memphis, TN
⁴St. Jude Children’s Research Hospital, Memphis, TN
⁵St. Jude Children's Research Hospital, Memphis
⁶Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
⁷St. Jude Children's Research Hospital, Department of Epidemiology and Cancer Control, Memphis, TN
⁸University of Pennsylvania School of Medicine, Philadelphia, PA
⁹St. Jude Children's Hospital, Memphis, TN
¹⁰Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
¹¹Saint Jude Children's Research Hospital, Memphis, TN
¹²St Jude Children's Research Hospital, Inc., Memphis, TN

5:00 PM

699

Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management

Jordan K Schaefer, MD, MSc¹, Josh Errickson, PhD²^*, Xiaowen Kong, MA³^*, Cherise Callahan, PharmD⁴^*, Christopher Giuliano, PharmD, MPH⁵^*, Mona A Ali, PharmD⁶^*, Naina Chipalkatti, MD⁷, Brian Haymart, RN, MS³^*, Scott Kaatz, DO, MSc⁸^*, Gregory D Krol, MD⁹^*, Noelle Ryan, PharmD¹⁰^*, Suman L Sood, MD, MSCE¹, James Froehlich, MD, MPH³^* and Geoffrey D Barnes, MD, MSc³^*

¹Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
²Consulting for Statistics, Computing, & Analytics Research, University of Michigan, Ann Arbor, MI, University of Michigan, Ann Arbor, MI
³Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
⁴Department of Pharmacy, Saint Joseph Mercy Ann Arbor, Ann Arbor, MI
⁵Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI
⁶Department of Heart and Vascular Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI
⁷Department of Internal Medicine, University of Michigan, Ann Arbor, MI
⁸Division of Hospital Medicine, Henry Ford Health, Detroit, MI
⁹Department of Internal Medicine, Henry Ford Health, Detroit, MI
¹⁰Ambulatory Anticoagulation Services, Henry Ford Health, Detroit, MI

5:15 PM

700

Clinical Outcomes after Hospitalization for Oral Anticoagulant-Related Bleeding

Nicholas L.J. Chornenki, MD, BSc¹, Joshua O Cerasuolo²^*, Aurélien Delluc, MD, PhD³^*, Anne Holbrook, MD, MSc, PharmD⁴^*, David Kirkwood²^*, Michael Paterson²^*, Rinku Sutradhar²^* and Deborah Siegal, MD, MSc³

¹Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
²Institute for Clinical Evaluative Sciences, Toronto, Canada
³Department of Medicine, University of Ottawa, Ottawa, ON, Canada
⁴McMaster University, Hamilton, ON, CAN

5:30 PM

701

Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis

Cho Han Chiang¹^*, Soravis Osataphan, MD²^*, Yu-Cheng Chang, MD³^*, Yu-Che Lee, MD⁴^*, Ko-Yun Chang, MD⁴^*, Cho-Hung Chiang, MD⁵^*, Mandy N. Lauw, MD, PhD⁶, Kenneth A Bauer, MD⁷, Dhruv S. Kazi, MD, MSc, MS⁸^* and Rushad Patell, MD⁹

¹Department of Medicine, Mount Auburn Hospital, Cambridge, MA
²Division of Medical Oncology and Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
³Department of Medicine, Danbury Hospital, Danbury, CT
⁴University at Buffalo, Buffalo
⁵National Taiwan University Hospital, Taipei, Taiwan
⁶Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
⁷Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA
⁸Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA
⁹Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA

5:45 PM

702

Impact of Thrombosis and Bleeding on Survival of Older People with Myelodysplastic Syndromes (MDS): A Population Analysis

Mansour Gergi, MD¹, Andrew Sparks, MS²^*, Neil Zakai¹ and Diego Adrianzen Herrera, MD, MSc³

¹University of Vermont, Burlington, VT
²Biomedical Statistics Research Core at the University of Vermont, Burlington, VT
³Larner College of Medicine at the University of Vermont, Burlington, VT

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

905.O1.6 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis